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Abstract Elevations of serum homocysteine levels are a
consistent ﬁnding in alcohol addiction. Serum S100B
levels are altered in different neuropsychiatric disorders
but not well investigated in alcohol withdrawal syn-
dromes. Because of the close connection of S100B to
ACTH and glutamate secretion that both are involved in
neurodegeneration and symptoms of alcoholism the rela-
tionship of S100B and homocysteine to acute withdrawal
variables has been examined. A total of 22 male and 9
female inpatients (mean age 46.9 ± 9.7 years) with an
ICD-10 diagnosis of alcohol addiction without relevant
affective comorbidity were examined on admission and
after 24, 48, and 120 h during withdrawal. S100B and
homocysteine levels in serum were collected, and severity
of withdrawal symptoms (AWS-scale), applied with-
drawal medication, initial serum ethanol levels and
duration of addiction were recorded. Serum S100B and
homocysteine levels declined signiﬁcantly (P\.05) over
time. Both levels declined with withdrawal syndrome
severity. Females showed a trend to a more intense
decline in serum S100B levels compared to males at day
5( P = .06). Homocysteine levels displayed a negative
relationship to applied amount of clomethiazole (P\.05)
and correlated with age of onset of addiction. No with-
drawal seizures were recorded during the trial. As it is
known for homocysteine, S100B revealed to decline
rapidly over withdrawal treatment in alcoholism. This
effect is more pronounced in female patients. S100B
could be of relevance in the neurobiology of alcohol
withdrawal syndromes. It may be indirectly related to the
level of stress level or glutamatergic activity during
alcohol withdrawal.
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Alcohol addiction and alcohol withdrawal syndromes have
been related to numerous biologic markers indicating
syndrome severity or detrimental effects. The GABAergic
system undergoes distinct adaptive processes over alcohol
addiction going in line with receptor down-regulation and
altered sensitivity [1]. During withdrawal, reduced GABA
agonistic effects coincide with an increase in glutamatergic
neurotransmission [2]. A compensatory up-regulation of
glutamatergic NMDA receptors over chronic alcohol
intake has been described [3].
Elevations of homocysteine and its main metabolite
homocysteic acid in serum are a consistent ﬁnding in
alcohol addiction [4–6] and withdrawal [7–9]. Due to
excitatory NMDA and glutamatergic effects and reduction
of inhibitory GABAergic drive by lack of ethanol, homo-
cysteine has been related to excitatory somatic and psychic
withdrawal symptoms, risk of withdrawal-related seizures,
and excitotoxic neurodegenerative phenomena [10–12].
S100 proteins are small, acidic proteins of 10–12 kDa.
S100B is a calcium-binding astroglial peptide which has
trophic or deleterious effects on neural cells in a dose-
dependent manner [13]. Mild S100B levels have been
associated with stimulatory effects on neuronal growth,
sprouting, and plasticity (e.g. concerning the central ner-
vous serotonergic system and a diminution of glutamate-
driven cytotoxicity) [14, 15]. High levels of S100B, on the
other hand activate early immediate genes (c-fos) [13] and
long-term high levels of S100B by increasing intracellular
calcium levels have been related to neurotoxicity and
degeneration at different sites [16]. Besides astrocytes and
other brain tissues [17], S100B is secreted by the follicu-
lostellate cells in the anterior pituitary after stimulation of
the stress axis and ACTH secretion [18]. Simultaneously,
glutamate synthetase is secreted from folliculostellate cells.
S100B has the highest density of intracellular binding sites
(receptor for advanced glycation end products: RAGE) in
neurons and glial cells of the hippocampus. Certain regions
of this structure have been reported to be highly vulnerable
to neurotoxic effects by S100B or glucocorticoids [13].
Such effects are thought to be glutamate driven.
Elevated levels of serum or cerebrospinal ﬂuid S100B
have been reported for psychiatric disorders such as
schizophrenia [19–21] or affective disorders [22–26] which
often co-occur with alcohol addiction [27, 28]. The role of
S100B in psychiatric disorders is still not very clear. Taken
together, it can be assumed that psychopathological alter-
ations in different syndromes represent a fairly unspeciﬁc
condition deriving from a general stress-level or increased
glutamatergic drive leading to conditions of restricted
declarative memory or emotional processing abilities.
There seems to be a crucial role of the central nervous
serotonergic system in this respect. On the one hand,
Serotonin 1a receptor stimulation increases S100B levels,
on the other hand S100B has been considered to improve
serotonergic neuron regeneration [29] most probably in
mild concentrations.
Data on S100B in addictive disorders, in particular in
alcohol dependence is still scarce. Animal data demon-
strated that S100B reduces ethanol-induced apoptosis [30].
One clinical study measure S100B in patients undergoing
inpatient withdrawal treatment assessed a signiﬁcant ele-
vation of S100B at admission compared to discharge after
approximately 4–5 weeks. However, this effect was only
found in patients with severe addiction and previously high
average alcohol consumption [31].
An association between homocysteine and S100B levels
over the alcohol withdrawal syndrome can be hypothesized.
Homocysteine levels correspond with NMDA and gluta-
mate activity in the withdrawal period. Neurotoxic effects
in certain brain areas correspond with dramatically raised
S100B levels. These are facilitated by glutamate activity.
However, mild S100B increases may diminish glutamate-
driven neurotoxicity. This study was performed in order to
further elucidate the role of S100B in alcohol withdrawal
syndromes and to correlate respective levels with with-
drawal syndrome severity and the well-known alterations in
serum homocysteine over the withdrawal period. Further-
more, it was of interest if values showed a connection to
addiction severity, duration of addictive drinking or gender.
Methods
The study was approved by the local ethics committee
Thirty-one inpatients undergoing a qualiﬁed alcohol with-
drawal treatment at the department of psychiatry and psy-
chotherapy of the University of Goettingen were included
into this study during October 2007 and August 2008.
Patients were males or females 18–70 years of age hospi-
talized for voluntary qualiﬁed detoxiﬁcation treatment and
suffering from alcohol addiction according to ICD-10 cri-
teria [32]. Patients with any psychotic symptoms, clinically
relevant major depression, polyvalent substance use
(except for nicotine), incapacitating organic brain disorder,
risk factors for hyperhomocysteinaemia, or regular psy-
chotropic drug treatment in the 4 weeks before admission
were excluded from participation. Subjects with relevant
language problems or patients unable to give free informed
consent were not included.
Patients were recruited within the ﬁrst 24 h after admis-
siontotheclinic.Aftercheckingforinandexclusioncriteria
and having given informed consent a serum sample for the
assessment of S100B, homocysteine, and alcohol
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drawn after 24, 48, and 120 h. On the latter 3 occasions, the
AWS scale [33] in order to assess withdrawal syndrome
severity was applied. Blood pressure and heart rate was
recorded on each of the 4 occasions, and the amount of
applied withdrawal-related medication during the past 24 h
was recorded. Blood ethanol concentration was controlled
24 h after the ﬁrst sampling. In the end of the study (120 h
after the ﬁrst blood sample), participants completed a
severity scale for alcohol addiction (MALT [34]). Sociode-
mographic data and information about duration of alcohol
addiction/age of onset of alcohol addiction was collected.
S100B was measured by ELISA according to Leite [35].
Fifty-microliter serum samples were analyzed using Clone
SH-B1 (Sigma Chemical Co.) as a capture antibody and a
polyclonal detecting antibody (Dako). Homocysteine was
measured by ELISA according the method described by
Frantzen [36]. Twenty-ﬁve-microliter serum samples were
analyzed using anti-SHA-antibody (Abbot Labs.) and
HRP-conjugated antibody (Dako).
Treatment during study
All participants received a qualiﬁed detoxiﬁcation treat-
ment with uniform supplementation of vitamins (B1, B6,
B12) and potassium (taken orally). Qualiﬁed detoxiﬁcation
treatment comprised psychosocial treatment (including
motivational training), physiotherapy and prescription of
withdrawal related medication following cardiovascular
monitoring.
Statistical analysis
Statistical analyses were performed by using SPSS (version
17.0). Pearson correlations were computed for age and
gender related to S100B and homocysteine at the respec-
tive time-points. Pearson correlations for S100B/homo-
cysteine and syndrome severity according to the AWS
score was calculated as well as for age of addiction onset
and duration of alcohol addiction and for applied clome-
thiazole medication.
Repeated measures analysis (ANOVA, SPSS method
Bonferroni) was performed for S100B, homocysteine, and
AWS scores over the study period. P values below .05
were considered signiﬁcant.
Results
Study population
Of the included 31 subjects (22 men, 9 women), 30 sub-
jects completed the trial. Subjects were between 28 and
68 years old (mean 46.9 ± 9.7). No signiﬁcant age dif-
ferences between men (45.8 ± 7.3) and women (49.4 ±
12.0) were detected. Mean duration of alcohol addiction
was 13.4 ± 8.7 years (range 1.5–33) mean age of onset of
addiction was at the age of 33.5 ± 10.5 years (range
19–60 years). Mean daily consumption of alcohol prior to
admission was 262 ± 124 g/day (range 95–631 g/day).
Mean blood alcohol concentration at the ﬁrst sampling
time-point was 1.41 ± 1.09 per mille (range 0–3.5 per
mille). MALT-scores had a mean of 15.5 ± 4.7.
Serum S100B and homocysteine
A comparable course was detected for S100B levels in
serum with a linear and signiﬁcant decline over the
investigational period. Mean baseline values, however,
were still in the normal range (74 ± 8 ng/l) and declined to
51 ± 6 ng/l over the following 120 h (F = 5.88; P\.05;
see Table 1). There was no signiﬁcant correlation between
age and homocysteine levels, neither was there any sig-
niﬁcant correlation between age and S100B levels.
On average, subjects displayed mildly elevated homo-
cysteine serum-levels at baseline (19.3 ± 2.2 lmol/l) that
declined signiﬁcantly over the following 120 h (F = 10.71;
P\.05; see Table 1). There was no signiﬁcant correlation
between age and homocysteine levels.
As an effect of gender, females displayed more rapidly
declining S100B values; however, this was just a statistical
trend (r = 0.35; P = .064; at 120 h; women vs. men).
A correlation between age of onset of alcohol addiction
and homocysteine levels could be detected. This correla-
tion was most evident from values after 48 h (r = 0.43;
P\.05) and was slightly less after 24 (P = .076) and
120 h (P = .052).
Another remarkable ﬁnding were the lower homocys-
teine levels after 24 h in patients the more clomethiazole
they received (r =- 0.64; P\.05). This effect could not
be demonstrated for the subjects receiving diazepam.
Table 1 Mean S100B and homocysteine serum levels over the
investigational period incl. 95% conﬁdence interval
0 h 24 h 48 h 120 h
Homocysteine lmol/l
Mean ± SD 19.3 ± 2.2 17 ± 1.4 14.8 ± 1.1 13.6 ± 1
95% CI 14.9–23.8 14.3–19.8 12.6–17.1 11.5–15.6
LOS vs. 0 h P\.05
S100B ng/l
Mean ± SD 74 ± 86 1 ± 95 4 ± 65 1 ± 6
95%CI 58–90 43–78 41–67 38–63
LOS vs. 0 h P\.05
SD standard deviation, CI conﬁdence interval, LOS level of
signiﬁcance
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and AWS-scores
Despite the linear decline of values for all three categories,
no signiﬁcant direct correlations could be detected between
these variables.
Withdrawal syndrome severity
No withdrawal related seizures nor any withdrawal delir-
ium was recorded in the sample over the study period.
AWS-scale
Scores on the AWS scale declined signiﬁcantly (F = 4.81;
P\.05) over time with highest scores after 24 h
(5.97 ± 2.97). Scores after 48 h were 4.63 ± 1.62 and
3.43 ± 0.96 after 120 h. There were no signiﬁcant differ-
ences in AWS-scores between men and women at any
assessment point.
Blood pressure and heart rate
Blood pressure showed a slight but non-signiﬁcant decline
between 24 and 120 h (145.5 ± 5.2 mmHg for systolic and
88.4 ± 8.5 for diastolic values at 24 h vs. 132 ± 16.2 for
systolic and 84.3 ± 9.4 at 120 h).
Heart rate declined non-signiﬁcantly over time
(94 ± 12.8 at 24 h vs. 85 ± 13 at 120 h).
Applied withdrawal medication
Clomethiazole (n = 13), diazepam (n = 12), phenobarbi-
tal (n = 3), and carbamazepine n = 11) were used in the
population. Phenobarbital was used for patients with mild
withdrawal syndromes who had adverse medication effects
from diazepam or clomethiazole during previous with-
drawal treatments.
Number of individuals treated with clomethiazole
decreased from 13 at time 0 h to 2 at 120 h. Applied
amount of clomethiazole decreased from a mean of
7.4 ± 4.2 capsules (192 mg each) at baseline to 1.5 ± 0.5
capsules at 120 h. Mean intake of clomethiazole capsules
did not differ between men (3.9 ± 3.0 capsules/day) and
women (3.5 ± 2.4 capsules/day). Three subjects did not
need any withdrawal-related medication.
Discussion
In support of our hypothesis, a signiﬁcant decline of serum
S100B levels over time could be detected, although aver-
age levels were in the normal range (compared to values
from the literature). However, 95% conﬁdence interval
values support the likelihood of higher S100B levels at the
beginning of withdrawal treatment. Although no direct
correlation with withdrawal severity according to the AWS
could be demonstrated, all 3 variables decline in a linear
fashion. S100B appears to be of certain relevance in the
biology of alcohol withdrawal syndromes, maybe giving
indirect reference to stress level or glutamatergic activity.
Probably these alterations are not particularly speciﬁc for
alcohol withdrawal syndromes. In major depression cor-
relations of S100B and symptom, severity could be dem-
onstrated and also in schizophrenia. Yet, these entities
represent syndromes connected to cognitive or emotional
impairment with distinct hippocampal impairment (e.g.
[37]). It could be speculated that S100B as well as homo-
cysteine are related to effects on e.g. hippocampal areas
that cause unspeciﬁc symptoms that occur in different
psychiatric disorders. Yet, actions of S100B are concen-
tration dependent. Those higher levels at baseline com-
pared to endpoint in this population are likely to be in the
neuroprotective and trophic range of S100B, and probably
represent a protective, counter-regulatory mechanism
against the harmful effects of hyperhomo-cysteinemia and
associated glutamate-mediated neurotoxicity.
Just slightly missing the level of signiﬁcance (P = .064;
r = 0.35) women tended to have lower level of serum
S100B at endpoint. This is a ﬁnding that in a way contra-
dicts the results by Yang [26] who found higher cerebro-
spinal ﬂuid S100B in depressed women compared to men.
However, women had no signiﬁcantly different withdrawal
severity scores according to the AWS scale. Neither were
women signiﬁcantly different with regard to age or in the
amount of applied withdrawal medication such as clome-
thiazole. Therefore, despite the small n, this may reﬂect a
gender effect. It could be hypothesized that neuroprotective
effects of S100B are expressed to a lower degree in female
alcohol addicted subjects. Age as well as blood ethanol
levels at admission were comparable in men and women.
One contributing factor, a lower average consumption of
alcohol prior to withdrawal in women compared to men,
cannot be excluded and would be in line with the ﬁndings
of Liappas et al. [31].
As expected, homocysteine serum values declined sig-
niﬁcantly from a moderately elevated level over the 120-h
investigational period in this population undergoing qual-
iﬁed alcohol detoxiﬁcation treatment.
One interesting issue deriving from our data is the sig-
niﬁcant inverse relationship between serum homocysteine
levels and clomethiazole intake. This effect was not
immediately observable but after 1 day of intake which
could represent an adaptive GABA mediated effect. In
contrast to this, S100B levels were not moderated by clo-
methiazole. Possibly, clomethiazole treatment may need to
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cysteine levels in alcohol addiction.
Correlations between homocysteine and age have been
consistently reported, and as a trend can be adapted from
our data. Also amount of alcohol intake prior to admission
has been found to be associated with higher serum homo-
cysteine. This may correspond with higher stress levels and
a higher risk for cardiovascular diseases. However, as
suggested by some authors (e.g. [38]), we could not ﬁnd
gender speciﬁc effects. Animal studies have indicated cir-
cadian variations of serum homocysteine and age-related
effects [39]. However, we could not detect any relationship
to age of subjects. Circadian shifts in homocysteine levels
were controlled by comparable time frames for all subjects.
The fact that our data revealed a positive correlation
between homocysteine serum levels and age of onset of
alcohol addiction appears surprising. It implies an associ-
ation between a shorter duration of the disorder with higher
serum levels of excitatory homocysteine. Alimentary rea-
sons for this effect due to reduced intake of methyl-group-
donators [40] can be hypothesized.
Nevertheless, the results presented here should not be
over-interpreted due to several limitations of the study. The
rather small study population was probably too heteroge-
neous. Less than a third (n = 9) of the subjects were
women, and the recruited subjects did not necessarily have
to have positive blood alcohol concentrations at inclusion.
Five patients in this population in fact were admitted to the
clinic without blood alcohol, whereas several previous
studies (e.g. [7, 8, 41] did not include patients with negative
blood alcohol due to a certain determination of homocys-
teine levels by the degree of blood ethanol levels [7].
According to our hypothesis of a diagnosis unspeciﬁc
phenomenon of elevated S100B in parallel with elevated
stress markers, we must admit that no statement at all on
HPA function can be made from our study. Compared to
another open-label study on S100B in alcohol withdrawal
by Liappas [31] who measured S100B levels in alcohol-
addicted subjects undergoing withdrawal treatment at
admission and at discharge (after 4–5 weeks), this appears
to be a clear limitation of that study. The investigational
period in this trial was very much shorter. It was compa-
rable with other investigations on homocysteine in alcohol
withdrawal (e.g. [7, 8] stressing the relevance of the acute
detoxiﬁcation period over the ﬁrst days of treatment.
Finally, although serum S100B measurements are a
valid measure, we cannot entirely exclude alterations of
blood–brain–barrier functioning in alcohol-addicted sub-
jects [42] as the cause of these slightly higher initial S100B
serum levels. One recent publication [43] identiﬁed the
body-mass-index (BMI) as a contributing factor to serum
S100B levels, which we did not take into account.
Conclusions
Serum S100B levels show a decline over a 5-day period
similar to homocysteine in alcohol-addicted subjects
undergoing acute inpatient alcohol withdrawal. Due to the
well-known concentration-dependent trophic or neurotoxic
effects of S100B, the demonstrated data may represent an
adaptive, counter-regulatory function of S100B protecting
sensitive neuronal brain structures against deleterious
effects mediated by homocysteine or glutamate. Further
investigations on larger populations taking HPA-function
into account appear useful. S100B serum levels and their
relationship to homocysteine in non-abstinent alcoholics
could be of interest due to the often postulated NMDA
balance of excitatory homocysteine and inhibitory, GAB-
Aergic ethanol effects.
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